the health system - lshprph aton rouge aton rouge (225)765-8441 (225) 231 [email protected] past...
TRANSCRIPT
NEWSLETTER OF THE LOUISIANA SOCIETY OF HEALTH-SYSTEM PHARMACISTS
26/2
MARCH/APRIL 2016
THE LA HEALTH-SYSTEM
PHARMACIST INSIDE THIS
ISSUE
FROM THE DESK OF THE PRESIDENT……………………...1
MEET THE BOARD……………2
UPCOMING EVENTS………..3
ASHP HOUSE OF DELEGATES UDATE…………..3
ENTREST®………………………..4
IVABRADINE…………………….5
LSHP MENTORSHIP PRGRAM….……………………..7
2016 ANNUAL MEETING….8
BOARD MEETING MOTIONS PASSED………………………….10
From the Desk of the President
Dear Members, I have been delayed writing this due to the rain/flooding taking part in most of our state. I hope that you and your family have weathered the storms as best as could be hoped for. It’s been a very trying time for pharmacists, technicians, customers and patients alike. Please keep those affected in your thoughts and help who you can. As my time winds down as President of this great society, I’d like to take a moment to reflect on the hard work and dedication of our volunteers. Specifically, I would like to thank the Executive Committee, Directors, Chapter Presidents, Board Members-Elect, Committee chairs and all the committee members who have given countless hours to the Society. Your dedication is appreci-ated by the Society and made my job much easier. I would also like to take the time to thank Bland O’Conner and the new Associ-ation Coordinator, Lauren Landry, for all the hard work they do for LSHP.
I would like to encourage you to continue to be involved and volunteer for LSHP as we enter another year. I know our Presi-dent-Elect, Jennifer Smith, would appreci-ate the same assistance as I enjoyed during my term. We invite you to our upcoming Annual Meeting May 26-28 at the Hyatt Regency New Orleans. We will have our annual re-ception kick-off at Rock-n-Bowl. We also have 26.5 Contact hours of CE; 16 hours for pharmacists, 10.5 hours for technicians. There will also be the annual awards cere-mony, poster presentations, the exhibit hall and the reverse expo. I hope to see you all down there! Thank you again for the great opportunity I had to serve you and the Society. It has been a pleasure and an honor. Sincerely, Shawn Manor LSHP President 2015-2016
Editor: Dana Jamero [email protected]
PRESIDENT– ELECT JENNIFER SMITH, PHARMD, BCPS BATON ROUGE (225)346-5961
PRESIDENT SHAWN MANOR, PHARMD, BCPS SHREVEPORT
(318) 632-2007 [email protected]
SECRETARY HELEN CALMES, PHARMD, MBA NEW ORLEANS (504) 460-6730
TREASURER TOMMY MANNINO,
RPH BATON ROUGE (225)765-8441
PAST PRESIDENT FANCY MANTON,
RPH, PHARMD BATON ROUGE (225) 231-5271
FANCY.MANTON@ WOMANS.ORG
MEMBER AT LARGE TERESA NASH, PHARMD, BCPS NEW ORLEANS (504) 842-3119
TNASH @OCHSNER.ORG
MEMBER AT LARGE FRANK MCCLOY, RPH
COVINGTON (985) 875-7291
EXT. 7594 FMCCLOY
@WARMSPRINGS.ORG
MEMBER AT LARGE MONICA MORGAN,
PHARMD LAFAYETTE
(337) 289-7886 MDMORGAN @LGMC.COM
MEMBER AT LARGE ELIZABETH PERRY,
PHARMD SHREVEPORT
(318) 632-2007 EXT. 245
BOARD MEMBER ELECT
ROXIE STEWART, PHARMD MONROE
(318) 342-1703 RSTEWART @ULM.EDU
CENTRAL JOSEPH G. LEBLANC JR.,
PHARMD, RPH (318) 769-3070
BOARD MEMBER ELECT
SCOTT DANTONIO, RPH
LUTCHER (225) 746-2945
SDANTONIO @SJPH.ORG
NORTH ASHLEY SADOWY,
PHARMD, BCPS (724) 683-2621
SOUTH CENTRAL ALEXIS HORACE,
PHARMD, BCACP, AAHIVP (225) 219-9660
SOUTH EAST CHRISTOPHER GILLARD,
PHARMD, BCPS (225) 315-7501
MEET THE LSHP BOARD OF DIRECTORS 2015-2016
THE LOUISIANA SOCIETY OF HEALTH SYSTEM PHARMACISTS 2
SOUTH WEST SHANE DOMINGUE,
RPH (337) 322-3788
LSHP BIMONTHLY NEWSLETTER LA HEALTH-SYSTEM PHARMACISTS PUBLISHER INFORMATION
The LA Health-System Pharmacist is published 6 times a year by the LSHP, 8550 United Plaza Blvd., Suite 1001, Baton Rouge, LA 70809. Subscription to the LA Health-System Pharmacist is a benefit of LSHP membership. All articles published represent the opinions of the authors and do not reflect the policy of the LSHP unless so specified. All student submissions must be reviewed by a pharmacist mentor whose name will be included on the article. Copy, advertising and nonmember subscription inquiries should be directed to the Copy Editor, Lauren Landry, at (225) 922-4520. Advertising rate sheets and deadlines are available upon request.
Please send article submissions to the newsletter editor, Dana Jamero, via email at [email protected].
THE LOUISIANA SOCIETY OF HEALTH SYSTEM PHARMACISTS 3
ASHP HOUSE OF DELEGATES UPDATE BY SCOTT DANTONIO, JOSEPH GARY LEBLANC, AND JENNIFER SMITH LSHP 2016 HOUSE OF DELEGATES
ASHP is now holding 2 virtual meetings of the House of Delegates each year in addition to the annual live meeting at the ASHP Summer Meeting. These vir-tual meetings are conducted via discus-sion on ASHP Connect followed by elec-tronic voting by the delegates. No edits or amendments can be made to policies during the virtual house, but if more than 85% of delegates approve a policy, it will become ASHP policy. If not ap-proved, the policy is referred to the live summer meeting for discussion and debate. The next virtual meeting will take place March 25th – April 1st. The policy rec-ommendations being discussed are: Direct-to-consumer advertising for
prescription drugs and implantable devices
Safety of the intranasal route as an alternative route of administration
Cultural competency and cultural
diversity Drug product supply chain integ-
rity The full text of the policy recommen-dations is available in the consolidat-ed documents for March virtual house at http://www.ashp.org/menu/PracticePolicy/HOD. There is also active discussion ongoing in ASHP Connect (connect.ashp.org). All ASHP members are encouraged to review the policies and associated discussion. Please let us know if you have any comments about how you wish your delegates to vote. Thanks! LSHP Delegates 2016 Scott Dantonio [email protected] Joseph Gary LeBlanc [email protected] Jennifer G Smith [email protected]
WELCOME 2016 NEW MEMBERS OF THE LSHP
Tammy Adams Stephanie Bui
Kelsey Dearman Jordan Laurent
Ladadriel Eastman Jana Treece
Ashley Joseph Stacey Rozas
Lauren Linder Cardez Ford
Anthony Walker Michelle Elloie
Stephanie Chang Sonja Peoples
Kirk Frank
UPCOMING EVENTS
MARCH 31, 2016 SELSHP
THERE’S AN APP FOR THAT!- HEALTH MANAGE-MENT MOBILE APPLICATIONS & THE ROLE OF
PHARMACY 6:30 PM
XAVIER UNIVERSITY OF LOUISIANA NEW ORLEANS, LA
APRIL 12, 2016 SCLSHP
OBESITY GUIDELINES: PHARMACOTHERAPY AS AN OPTION
6:30 PM WOMEN’S HOSPITAL
BATON ROUGE, LA
APRIL 26, 2016 NLSHP
SUPPLEMENT REVIEW FOR PHARMACISTS 7:00 PM
ULM SCHOOL OF PHARMACY SHREVEPORT, LA
MAY 26-28, 2016 2016 LSHP ANNUAL MEETING
HYATT REGENCY NEW ORLEANS, LA
SEPTEMBER 30– OCTOBER 1, 2016
2016 LSHP MID YEAR MEETING SHREVEPORT CONVENTION CENTER
SHREVEPORT, LA
THE LOUISIANA SOCIETY OF HEALTH SYSTEM PHARMACISTS 4
ENTRESTO® (SACUBITRIL AND VALSARTAN): A NEW AGENT DEMONSTRATING SUPERIORI-TY TO ACE INHIBITORS IN THE REDUCTION OF MORTALITY IN HEART FAILURE BY CHRISTOPHER J. GILLARD, PHARMD, BCPS
Heart failure is a highly debilitating, life-threatening condition in which the heart cannot pump enough blood to the systemic circulation be-cause the muscles of the heart become too weak or too stiff to work properly.1 Patients face a high risk of death, repeated hospitalizations and symptoms such as breathlessness, fatigue and fluid retention that significantly impact quality of life. In the United States, about 5.1 million people have heart failure. About 50% of patients who are diagnosed with heart failure die within five years of diagnosis.2 Heart fail-ure has been associated with over $30 billion annual medical cost each year. The 2013 American College of Cardiology Foundation/American Heart Associa-tion (ACCF/AHA) Guidelines classify heart failure as heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF).3 Several classes of medications have been shown to reduce heart failure associated symptoms and outcomes including beta receptor antagonists, ACE inhibitors, angiotensin receptor blockers (ARB), diuretics, aldosterone antagonists, and digoxin. 3 The Food and Drug Administration recently approved Entresto® (sacubitril and valsartan) on July 8, 2015 to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.4 Entresto® is a combination of an angiotensin receptor antagonist (valsartan) and a neprilysin inhibitor (sacubitril).5 The positive cardio-vascular effects of Entresto® are due to increased levels of natriuretic peptides degraded by neprilysin and the concurrent inhibition of angiotensin II by valsartan which eventually leads to a reduction in aldosterone, reduced sympathetic tone, and diure-sis. These are all desirable clinical effects in heart failure.5 The PARADIGM-HF of 2014 was a random-ized clinical trial including 8,442 patients with NYHA Class II-IV heart failure with an ejection fraction
<40% that compared sacubitril and valsartan (200 mg twice daily) to enalapril (10 mg twice daily).6 The trial was stopped early because of the over-whelming benefit of the sacubitril and valsartan group. The primary outcome (composite of death from cardiovascular causes or hospitalization for heart failure) occurred in 21.8% of patients versus 26.5% in those on enalapril (p<0.001).6 Additional-ly, as compared with enalapril, sacubitril and valsar-tan reduced the risk of hospitalization for heart fail-ure by 21% (p<0.001) and decreased symptoms of physical limitations of heart failure (p=0.001).6 The starting dose of Entresto® is 24 mg (sacubitril)/26 mg (valsartan) twice daily and should be doubled in 2-4 weeks to 49/51 mg twice daily as tolerated. The target maintenance dose is 97/103 twice daily.5 The medication dose should be titrated per the available dosing guide for patients being switched from an ACE inhibitor or ARB. No starting dose adjustment is needed for mild to moderate re-nal impairment and hepatic impairment. Entresto® is not recommended for patients with severe he-patic impairment. Adverse reactions (≥5%) include hypotension, hyperkalemia, cough, dizziness, and increase in serum creatinine. 6 Entresto® should not be administered with an ACE inhibitor or ARB as dual blockade of the renin-angiotensin system is not rec-ommended and it should be avoided in pregnancy as it can cause fetal harm. Hyperkalemia may occur with Entresto®, monitoring serum potassium period-ically is recommended.5 The average wholesale price for Entresto® is $450 for a month supply (60 tablets) of the 24/26 mg, 49/51 mg, or 97/103 mg tablets.7 Patient assistance is available on the drug manufacturer website. 8 Early clinical trial results for Entresto® (sacubitril and valsartan) are very promising and ad-ditional studies are being conducted at this time for more efficacy data. This new drug has shown consid-erable reductions in cardiovascular mortality and
Entresto® continued on page 5
THE LOUISIANA SOCIETY OF HEALTH SYSTEM PHARMACISTS 5
heart failure hospitalization compared to ACE inhibi-tors such as enalapril, which is a Class I guideline rec-ommended agent.3,6 The (ACCF/AHA) clinical guide-lines will most likely address the new agent’s place in heart failure therapy for clinicians in the near future. References: 1. Centers for Disease Control and Prevention: Heart
Failure Fact Sheet. 2015 2. Go A, Mozaffarian D, Roger V. Heart disease and
stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013 Jan 1;127(1):e6-e245.
3. ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiolo-gy Foundation/American Heart Association Task Force
on Practice Guidelines. Circulation. 2013 4. FDA approves new drug to treat heart failure. FDA
News Release. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm. Published July 8, 2015. Accessed January 15, 2016.
5. Entresto *package insert+. East Hanover, NJ. Novartis 2015.
6. McMurray J, Packer M, Desai A. Angiotensin-neprilysin inhibition versus enalapril in heart failure (The PARADIGM-HL Trial). N Engl J Med. 2014 Sep 11;371(11):993-1004.
7. Lexi Comp Online Drug Information Reference. Ac-cessed January 15, 2016.
8. Novartis Drug Website. http://entresto.com/
index.jsp
Entresto® continued
IVABRADINE (CORLANOR®): A NEW TREATMENT TO REDUCE HOSPITAL ADMISSION IN HEART FAILURE PATIENTS BY KELSEY DEARMAN, PHARMD CANDIDATE AND TIBB JACOBS, PHARMD
Chronic heart failure is related to increased morbidity and mortality, and is the primary diagno-sis in over one million hospitalizations every year. After one month, 25% of patients treated for hospi-talized heart failure will be readmitted.1 Heart fail-ure comes at a high price, both in patient lives and cost of treatment. In 2013, the total cost of heart failure treatment in the United States was over $30 billion, with hospitalizations accounting for more than half of the costs.1 The total cost of healthcare for heart failure is projected to increase to $70 bil-lion by 2030.1 Heart failure exhausts patient and hospital resources, both physically and financially. A major risk factor for cardiovascular disease and heart failure is increased resting heart rate, also known as tachycardia. Tachycardia will raise myo-cardial oxygen demand, reduce energy, and lead to plaque rupture.2 Although these factors contribute to increased cardiovascular risk, they have the po-tential to be managed and modified in patients. Be-ta-blockers (e.g. metoprolol and carvedilol) and ren-in-angiotensin-aldosterone system antagonists (eg. lisinopril and captopril) are customary pharmacolog-ical treatments for heart failure. Beta-blockers have
been successful at decreasing morbidity and mortali-ty in some heart failure patients by lowering resting heart rate. However, numerous patients maintain increased resting heart rate despite treatment with these agents.3 In order to improve patient outcomes and the use of financial resources, new mechanisms of targeting elevated heart rate have been explored. Corlanor®, also known by generic name ivabradine, is the latest agent developed for heart failure, and the first of a new class of drugs that ex-clusively lowers heart rate. Ivabradine selectively inhibits If current, which alters pacemaker activity in the sinoatrial node and leads to a reduction in heart rate.2 In contrast to beta-blockers, ivabradine de-creases heart rate without directly affecting other cardiovascular dynamics.3,4 Ivabradine is available in 5 mg and 7.5 mg tablets. The recommended starting dose of ivabra-dine is 5 mg twice daily. If the resting heart rate is still above 60 bpm after two weeks, patients may be titrated up to 7.5 mg twice daily. A 2.5 mg twice-daily dose is advised for patients aged 75 years or older, as well as for patients whose resting heart rate falls below 50 bpm after treatment with ivabra-
Ivabradine continued on page 6
THE LOUISIANA SOCIETY OF HEALTH SYSTEM PHARMACISTS 6
dine. There is no dose adjustment necessary in pa-tients with renal insufficiency or mild hepatic injury. Ivabradine should be taken with meals, as food sig-nificantly enhances drug absorption. Ivabradine is supplied in bottles of 60 or 180 tablets, and should be stored at room temperature. The most commonly reported side effects of ivabradine include increased blood pressure, brady-cardia, atrial fibrillation, and visual brightness.5 Pa-tients are advised to report symptoms of bradycar-dia such as dizziness or fatigue. Patients should also be counseled on the symptoms of atrial fibrillation such as chest pressure, heart palpitations, and short-ness of breath. Ivabradine should be discontinued if atrial fibrillation develops. Temporary visual bright-ness, also known as phosphenes, typically appears within the first two months of treatment.4,5 Patients should be advised to exercise caution when driving, especially at night, or operating heavy machinery while taking this medication. Ivabradine poses po-tential harm to the fetus and is classified as Pregnan-cy Category D.5 Women of reproductive age should use reliable contraception and should contact their provider immediately if they become pregnant or suspect pregnancy. Ivabradine is contraindicated in patients with acute decompensated heart failure, blood pressure less than 90/50 mmHg, resting heart rate less than 60 bpm before treatment, severe hepatic impair-ment, sick sinus syndrome, sinoatrial block, 3rd de-gree AV block, exclusive pacemaker dependence, and concurrent use of strong CYP3A4 inhibitors.5 As this agent is predominantly metabolized by CYP3A4, concurrent use of CYP3A4 inhibitors increases ivabradine plasma concentrations, and is therefore not recommended. Examples of strong CYP3A4 in-hibitors to avoid include azole antifungals, macrolide antibiotics, HIV protease inhibitors, and nefazadone. Moderate CYP3A4 inhibitors such as diltiazem, vera-pamil, and grapefruit juice should also be avoided in patients taking ivabradine. CYP3A4 inducers will in-crease metabolism of ivabradine and decrease plas-ma drug concentrations. CYP3A4 inducers include St. John’s wort, rifampicin, barbiturates, and pheny-
toin, and should not be administered concomitantly with ivabradine. A randomized, double blind, placebo-controlled study, known as the SHIFT trial, was con-ducted in patients with chronic heart failure to de-termine the safety and efficacy of ivabradine on low-ering heart rate. Ivabradine significantly decreased the risk of cardiovascular death and hospitalization due to heart failure by 18%, as compared to the pla-cebo.2,3 The positive effects of treatment with ivabradine were seen within three months of treat-ment and remained for the duration of the study.2,3 This result shows the potential for ivabradine to play an instrumental role in improving heart failure and cardiovascular risk, decreasing the likelihood of hos-pital readmissions, and decreasing the financial bur-den of heart failure on hospitals and patients. In an-other recent study, ivabradine and traditional beta-blockers were compared for efficacy and safety in a clinical setting. Ivabradine showed fewer side effects compared to beta-blockers, as ivabradine acts selectively on If channels.6 This finding lead re-searchers to conclude that ivabradine can be used in conjunction with beta-blockers to improve patient outcomes and as a beneficial alternative in those who do not tolerate beta-blocker therapy.6 With re-gards to safety, ivabradine is well tolerated when administered alone, with beta-blockers, or with oth-er cardiovascular treatments.2 This drug is also safe-ly used in patients with comorbidities such as asth-ma, chronic obstructive pulmonary disease, and dia-betes mellitus.2 Approval of ivabradine could benefit patients with heart failure by selectively lowering elevated heart rate. By improving heart rate in this popula-tion, ivabradine could reduce hospital admissions, decrease healthcare expenses, and improve patient quality of life. References:
1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology founda-tion/american heart association task force on prac-
Ivabradine continued
Ivabradine continued on page 7
THE LOUISIANA SOCIETY OF HEALTH SYSTEM PHARMACISTS 7
2016 LSHP MENTORSHIP PROGRAM Our LSHP mentorship program will provide professional growth to new practitioners and students. Please read the information below and if you are interested, please click the link and fill out the appropriate form. Goals The goal of the program is to provide mentorship opportunities to leaders and future leaders of the society through a program designed to develop, inspire, and encourage involvement in the profession. In doing so, this will allow new practitioners and their mentoring pharmacists to expand their professional network, share and learn from experience, and develop the future generation of our profession. Networking Opportunities A networking event will be organized during the May Annual Meeting to further opportunities for new prac-titioners and mentor pharmacist to meet face-to-face. This should not prohibit your regional chapter from organizing additional events with the new practitioners to network with the future leaders of our profession. Mentorship Role To Develop a relationship based on trust
Share critical knowledge Act as a confidential adviser
Be a positive role model for leadership in the profession of pharmacy Provide feedback/mentorship and constructive coaching
Commit time and energy to the relationship (1 year commitment April 2016 - April 2017) Mentee Role: Drive the mentoring relationship
Take ownership of career and personal development
Be open to constructive feedback and coaching Maintain confidentiality
Create and act on development goals/plans Commit time and energy to the relationship Time Commitment Mentors and mentees are required to communicate at least quarterly throughout the year. This communica-tion will be established between the mentor and new practitioner (eg. phone, email, or face to face). The new practitioner will always contact the mentor to set up a time and date for such occurrences. Mentor Form: https://www.surveymonkey.com/r/9VG5PSS Mentee Form: https://www.surveymonkey.com/r/9VCH5VX Questions/Comments As this is a new and exciting initiative, we welcome continuous feedback and look forward to hearing your stories about the successes and challenges you faced in organizing the mentorship program. If you have any questions regarding the program, please feel free to address to Alexis E. Horace ([email protected]) and Katie Ducote ([email protected])
General Information Overall Meeting Objectives & Target Audience To provide information and instruction on a variety of topics to enhance pharmacists’ training and skills and to provide pharmacists, pharmacy technicians, and pharmacy students with instruction on important drug therapy, general pharmacy, patient safety, and legal and regulatory matters relevant to current pharmacy practice in Louisiana and the United States. Fees Please see the registration form in this brochure for all applicable registration fees. Schedule of Educational Activities A schedule of all educational events at the 2016 Annual Meeting can be found on the following pages. The Universal Activity Numbers, which indicates target audiences for each activity, are included on the schedule. Continuing Education Credit A total of 17 contact hours (1.6 CEUs) are scheduled during the Annual Meeting, of which a maximum of 17 contact hours (1.7 CEUs) can be earned by a pharmacist and a total of 10.5 hours (1.05 CEUs) can be earned by a pharmacy technician. To receive credit for an activity, registrants must attend the activity; complete a Continuing Education Credit Report, including the Activity Evaluation, and submit onsite at the end of the meeting; and pay all applicable LSHP fees. To receive credit for the poster session, registrants must attend the interactive portion of the poster session, complete the questions for each poster in the packet provided, submit the completed packet to the registration desk, and indicate your attendance for the poster session on your Continuing Education Report Form. LSHP will issue credit electronically via CPE Monitor. You must provide your NABP e-Profile ID and day of birth on your Continuing Education Report Form in order to receive credit. LSHP is no longer issuing paper statements of credit. Accreditation
The Louisiana Society of Health-System Pharmacists, American Society of Health-System Pharmacists, The Medical Learning Institute, Inc., and the American Association of Diabetes Educators are accredited by the Accreditation Council for Pharmacy Education as
providers of continuing pharmacy education. Thursday Welcome Reception Reserve your ticket on the registration form and join us for LSHP’s traditional Thursday evening Welcome Reception at New Orleans iconic Rock ’n’ Bowl, located at 3000 S. Carrollton Avenue. Kick off the Annual Meeting while eating, drinking, dancing and bowling the night away with old friends and colleagues from around the state. The party will be from 7:00-9:30 p.m. Exhibit Program An outstanding exposition has been planned for the Annual Meeting, displaying the latest pharmaceutical developments, products, equipment and services available. The expo will provide an excellent opportunity for you to visit with your colleagues and local industry representatives on Friday, May 27 from 12:00 to 3:00 p.m. Poster Presentations A poster session will be held Friday, May 27, 2016 from 12:00 to 3:00 p.m. Achievement awards, as well as a cash award, will be presented. The interactive portion offered for continuing education credit will be from 2:00-3:00 p.m. Check the LSHP website,
www.lshp.org, for more information on submitting a poster. General Membership Meeting All LSHP members in good standing are encouraged to attend the General Membership Meeting to be held Friday, May 27, 2016 from 9:00 a.m. to 10:00 a.m. The General Membership Meeting is an open forum for members to discuss pharmacy topics affecting their profession. The presentation of awards will also be held at this meeting. Hotel The conference hotel is the Hyatt Regency, located at 601 Loyola Ave . Reservations may be made by calling the Hyatt Regency at (888) 421-1442 or by going to the following link: https://resweb.passkey.com/go/LSHPannualmeeting2016 . Rooms are $155 per night for single or double occupancy, plus state and local taxes. Rooms must be booked by April 25, 2016 to be included in the LSHP room block. When you reserve your room, please let them know that you are with LSHP to receive the discounted room block rate. Cancellations and Refunds To receive a refund, confirmed registrations must be cancelled in writing. A $15 administrative fee will be charged for all refunds. No refunds will be issued for requests faxed or postmarked after May 20, 2016. Arrangements for Special Assistance/ Questions about Registration If you have a disability for which you require special accommodations while attending the meeting, or have questions about registering, please contact the LSHP at (225) 922-4520. Parking Special valet parking rates have been arranged for LSHP Hyatt overnight guests of $20 per night for standard vehicles. Parking is also available in the Platinum Parking garage at 1301 Girod Street, which connects to the Hyatt. Rates are: $12 for 3-9 hours; $20 for 9-12 hours; $25 for 12-24 hours. Parking is also available within walking distance to the Hyatt in the Superdome and in open lots bordering South Rampart, Lafayette and Okeefe Streets. New Mentorship Program LSHP has developed a mentorship program to aid in the professional growth of new practitioners. The New Practitioner Committee has formalized this program state-wide to provide consistent oversight and leadership. The goal of the program is to provide mentorship opportunities to leaders and future leaders of the society through a program designed to develop, inspire, and encourage involvement in the profession. In doing so, this will allow new practitioners, students and their mentoring pharmacists to expand their professional network, share and learn from experience, and develop the future generation of our profession. The Mentorship Program is available to both students and New Practitioners. Mentors and their mentees will have an opportunity to meet face-to-face at the Annual Meeting at 4:00 pm on Friday, May 27 after the Student Session.
To register online visit:
http://lshp.org/2016AnnualMeeting
LSHP 2016 Annual Meeting Registration Form
Space is limited. Please reserve your seat. Tickets will only be distributed to pre-registrants.
□ Welcome Reception (Rock ‘n’ Bowl) Thursday 5/26/2016
□ I will bring a guest/spouse. _____ $40 Guest Name:________________________________________________
PAYMENT: ___Check ___Visa ___MasterCard ___American Express Name on Card:________________________________________ Credit Card No.: _______________________________Exp. Date: ______ CVV: ______ Billing Address for Card (If different from above address):__________________________________________________________________
Signature: ____________________________________________________ Make checks payable to LSHP or provide credit card information and mail or fax to
LSHP, 8550 United Plaza Blvd, Suite 1001, Baton Rouge, LA 70809 Fax (225) 408-4422.
Contact the LSHP office if you have a disability and need special assistance, or have special dietary needs You may also register online by going to the following link— http://lshp.org/2016AnnualMeeting
OFFICE USE ONLY: RECEIVED: ___________ PROCESSED: _________ CHECK #/ CC: _____________ CONF:______________
Discount for early registration if postmarked by May 11, 2016
Name: _______________________________________________________ Badge Name:________________________________
NABP e-Profile ID#: ____________________________________ Month and Day of Birth (MM/DD): __________ /___________
Institution/Affiliation: ____________________________________________ Position/Job Title: __________________________
Designation: ___ Pharm.D. ___ R.Ph ___ Technician ___ Other ____________________________________________
Home Address: ______________________________________ City/State/Zip:_________________________________________
Business Phone: _________________________________Email:_____________________________________________________
Late registration fee if postmarked after May 11, 2016 _____ $20
TOTAL AMOUNT: _____
Contribution for student sponsorship to attend the Annual Meeting ($30, $50, $75, $100) _____
Registration
LSHP Pharmacist Member Full Registration _____ $175 Thursday only _____ $80 Friday only _____ $120 Saturday only _____ $100 Pharmacist Non-Member Full Registration _____ $270 Thursday only _____ $130 Friday only _____ $170 Saturday only _____ $150 LSHP Technician Member Full Registration _____ $115 Thursday only _____ $45 Friday only _____ $65 Saturday only _____ $55
Annual Meeting registration includes admission to all educational sessions, meals and social events. You must indicate below if you are attending the Welcome Reception. Non-member Full Registration includes membership for the remainder of the 2016 year. *Hospital Administrators accompanied by their director of pharmacy fully registered for the meeting are offered complimentary registration. However, please submit a registration form for the administrator.
TECHNICIAN NON-MEMBER FULL REGISTRATION _____ $155
THURSDAY ONLY _____ $70
FRIDAY ONLY _____ $95
SATURDAY ONLY _____ $85
PHARMACY RESIDENT FULL REGISTRATION _____ $115
THURSDAY ONLY _____ $45
FRIDAY ONLY _____ $65
SATURDAY ONLY _____ $55
STUDENT FULL REGISTRATION _____
$30 (DOES NOT INCLUDE WELCOME RECEPTION) STUDENT TRACT ONLY _____ $5 (DOES NOT INCLUDE LUNCH, ONLY STUDENT TRACT SESSIONS)
WELCOME RECEPTION TICKET _____
___ Please check here if you are receiving complimentary registration for Pharmacy Directors and Clinical Managers participating in the Reverse Expo on Thursday, May 26. (You must also complete the “Pharmacy Directors Forum and Reverse Expo Registration Form.”
Technician Non-Member Full Registration _____ $155 Thursday only _____ $70 Friday only _____ $95 Saturday only _____ $85 Pharmacy Resident Full Registration _____ $115 Thursday only _____ $45 Friday only _____ $65 Saturday only _____ $55 Student Full Registration _____ $30 (Does not include Welcome Reception) Student Tract Only _____ $5 (Does not include lunch, only Student Tract Sessions) Welcome Reception Ticket _____ $10
Optional Items:
Spouse/Guest Exhibit Lunch ___ $30
Printed Program Book ___ $20
LSHP Lapel Pin ___ $5
MOTIONS PASSED BOARD OF DIRECTORS MEETING
Listed below are the motions passed from the 2016 Board of Directors Meeting on January 29, 2016: A new marketing plan, including institutional memberships, membership promotions, a sponsorship program, up-
dates to the LSHP Website and Newsletter was approved. Additions to the Annual Meeting Student Tract including a virtual showcase were approved . The 2016 LSHP MYM Contract with the Shreveport Convention Center was approved for September 30– October 1,
2016. A rollover date of October 1st was approved for memberships.
tice guidelines. Circulation. 2013;128:240-327. 2. Deedwania P. Selective and specific inhibition of If of
ivabradine for the treatment of coronary artery dis-ease or heart failure. Drugs. 2013;73:1569-1586.
3. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (shift): a ran-domised placebo controlled study. Lancet. 2010;376:875-885.
4. Speranza L, Franceschelli S, Riccioni, G. The biological effects of ivabradine in cardiovascular disease. Mole-cules. 2012;17:4924-4935.
5. Corlanor® *package insert+. Thousand Oaks, CA: Amgen Inc; 2015.
6. Di Franco A, Sarullo F, Salerno Y, et al. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. American Journal of Cardio-vascular Drugs. 2014;14:101-110.
Ivabradine continued
8550 United Plaza Blvd Suite 1001 Baton Rouge, LA 70809